The pharmacokinetics of etanercept in patients with heart failure.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  British Journal of Clinical Pharmacology

• Publication date

  2001-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/J.1365-2125.2001.01279.XPMID 11259995PMCID PMC2014439
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Pharmacokinetics of Etanercept in Healthy Volunteers

  2000cited by this paper
• Etanercept: a review of its use in rheumatoid arthritis.

  1999cited by this paper
• An overview of tumor necrosis factor α and the failing human heart

  1999cited by this paper
• Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD).

  1996cited by this paper
• Drug-patient interactions and their relevance in the treatment of heart failure.

  1992cited by this paper
• Elevated circulating levels of tumor necrosis factor in severe chronic heart failure.

  1990cited by this paper
• Clinical Pharmacokinetics in Heart Failure

  1988cited by this paper
• Clinical pharmacokinetics in heart failure. An updated review.

  1988cited by this paper

• Pharmacokinetic Alterations in Patients with Chronic Heart Failure: A Systematic Review

  2025cites this paper
• Validation of a Test System Based on Enzyme-Linked Immunosorbent Assay for the Evaluation of Etanercept Pharmacokinetics in Patients

  2023cites this paper
• TNF‐α level affects etanercept clearance: TNF‐α concentration as a new correction factor of allometric scaling to predict individual etanercept clearances in patients with ankylosing spondylitis

  2018cites this paper
• Clinical Pharmacokinetics of Drugs in Patients with Heart Failure

  2013cites this paper
• Clinical Pharmacokinetics of Drugs in Patients with Heart Failure: An Update (Part 2, Drugs Administered Orally)

  2013cites this paper
• Drug–Drug Interactions for Etanercept—A Fusion Protein

  2013cites this paper
• Spotlight on Etanercept in Rheumatoid Arthritis, Psoriatic Arthritis and Juvenile Rheumatoid Arthritis

  2012cites this paper
• Etanercept: overview of clinical experience in the treatment of psoriasis and psoriatic arthritis

  2011cites this paper
• Tumor necrosis factor triggers the expression and activation of matrix metalloproteinases through NADPH-dependent superoxide production

  2010cites this paper
• TNF alpha—Still a Therapeutic Target

  2008cites this paper
• Effect of the Soluble TNF‐Antagonist Etanercept on Tumor Necrosis Factor Bioactivity and Stability

  2008cites this paper
• Etanercept: long-term clinical experience in rheumatoid arthritis and other arthritis

  2007cites this paper
• Etanercept: a review of its use in the management of rheumatoid arthritis.

  2007cites this paper
• Mechanism of Action, Pharmacokinetics, and Drug Interactions of Etanercept in Dermatology

  2007cites this paper
• The Comparability of Etanercept Pharmacokinetics in Healthy Japanese and American Subjects

  2006cites this paper
• Clinical Pharmacokinetics of Etanercept: A Fully Humanized Soluble Recombinant Tumor Necrosis Factor Receptor Fusion Protein

  2005cites this paper
• Population Pharmacokinetic Analysis and Simulation of the Time‐Concentration Profile of Etanercept in Pediatric Patients With Juvenile Rheumatoid Arthritis

  2005cites this paper
• Anti-tumour necrosis factor therapy in congestive heart failure: What went wrong?

  2003cites this paper
• Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis.

  2002cites this paper